The overall 5-year survival rate of<unk>  has been given as 7% or 14%, although the latter has been criticized as being overestimated. Additional factors that affect prognosis include the person's age, the presence of distant metastases, the dose of radiation administered to the primary tumor and regional lymph nodes, and if combined modality treatment is used. Treatment of<unk>  is generally palliative in its intent due to its highly aggressive nature and nearly universal mortality. Larger tumors, distant metastases, acute obstructive symptoms, and leukocytosis portend a poorer prognosis. Death is attributable to upper airway obstruction and suffocation in half of patients, and to a combination of complications of local and distant disease, or therapy, or both in the remainder.<unk>  is extremely aggressive; historically, in most cases death occurs in less than 1 year as a result of aggressive local growth and compromise of vital structures in the neck.<unk>  in most series has a median survival of 4 to 5 months from the time of diagnosis, with rare long-term survivors. Recent data however suggests that patients with BRAFV600E mutated disease, even if in an advanced stage, may have significantly better prognosis, as novel targeted therapies can extend tumor control considerably, while also leading to tumor burden decrease and potentially make patients candidates for surgery. Recent advances show that using a combination of novel targeted therapies, immunotherapy, and surgery, 1 year and 2 year survival for<unk>  patients have increased to 59% and 42%, respectively.
Anaplastic thyroid cancer
Thyroid lymphoma
Follicular thyroid cancer
Papillary thyroid cancer
Medullary thyroid cancer
Squamous-cell thyroid carcinoma
Poorly differentiated thyroid cancer
Thyroid adenoma